Potassium News and Research

RSS

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

FDA approves fampridine-SR drug for treatment of multiple sclerosis

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease - and their efforts helped pave the way for today's action by the FDA.

23 Jan 2010

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010

Most Americans knowledgeable about heart health, but do not exercise or maintain a healthy diet

A new survey of American adults revealed that while most feel knowledgeable when it comes to heart health, many do not put their knowledge into practice. In fact, 81 percent of respondents reported feeling well-informed about ways to maintain heart health and almost nine out of 10 knew they could help reduce the risk of heart disease by exercising and maintaining a healthy diet.

20 Jan 2010

Protein supplements do not improve athletes' performance

Protein supplements don't improve performance or recovery time and, according to a recent study, such supplements are inefficient for most athletes. "They are often poorly used or unnecessary by both high-level athletes and amateurs," says Martin Fr-chette, a researcher and graduate of the Universit- de Montr-al Department of Nutrition.

20 Jan 2010

Eating strategies can reduce cell damage and enhance sports performance

For a week Ms Gravina evaluated players from the first two Athletic teams (Superleague and National League), in order to observe their eating habits and where they could improve.

19 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

CLSI’s document provides revised guidelines for screening cystic fibrosis

Clinical and Laboratory Standards Institute (CLSI) recently published Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition (C34-A3). This document addresses appropriate methods of collection and analysis, quality control, and the evaluation and reporting of sweat test results for the diagnosis of cystic fibrosis.

7 Jan 2010

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.

6 Jan 2010

Study reveals molecular mechanism that could lead to new approach in treating obesity

Mayo researchers collaborating with investigators at the University of Iowa, University of Connecticut and New York University (NYU) have discovered a molecular mechanism that controls energy expenditure in muscles and helps determine body weight. Researchers say this could lead to a new medical approach in treating obesity.

5 Jan 2010

Nukepills.com delivers 5.4 million doses of Potassium Iodide to protect people from nuclear radiation

For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.

31 Dec 2009

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

30 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Cumberland Pharmaceuticals Inc. (CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms.

16 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals, Ltd. today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

10 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

Potassium News and Research

Biogen Idec's statement on FDA approval of AMPYRA

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

FDA approves fampridine-SR drug for treatment of multiple sclerosis

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Most Americans knowledgeable about heart health, but do not exercise or maintain a healthy diet

Protein supplements do not improve athletes' performance

Eating strategies can reduce cell damage and enhance sports performance

First sulfite-free rectal suspension for UC

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

CLSI’s document provides revised guidelines for screening cystic fibrosis

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

Study reveals molecular mechanism that could lead to new approach in treating obesity

Nukepills.com delivers 5.4 million doses of Potassium Iodide to protect people from nuclear radiation

FDA accepts NDA review for new anticonvulsant drug

Pistachios can decrease inflammation and cardiovascular disease

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News